# Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)

> **NCT03833427** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 32 (actual)

## Conditions studied

- Advanced/Metastatic Solid Tumors

## Interventions

- **DRUG:** Selumetinib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03833427
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-18
- **Primary completion:** 2022-06-28
- **Final completion:** 2022-06-28
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03833427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03833427, "Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03833427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*